A detailed history of Harbour Capital Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Harbour Capital Advisors, LLC holds 6,286 shares of VRTX stock, worth $3.25 Million. This represents 0.7% of its overall portfolio holdings.

Number of Shares
6,286
Previous 6,200 1.39%
Holding current value
$3.25 Million
Previous $2.91 Million 0.58%
% of portfolio
0.7%
Previous 0.71%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

BUY
$460.0 - $505.78 $39,560 - $43,497
86 Added 1.39%
6,286 $2.92 Million
Q2 2024

Jul 12, 2024

BUY
$392.81 - $485.53 $261,218 - $322,877
665 Added 12.01%
6,200 $2.91 Million
Q1 2024

Apr 16, 2024

BUY
$407.69 - $446.08 $27,722 - $30,333
68 Added 1.24%
5,535 $2.31 Million
Q4 2023

Jan 05, 2024

BUY
$343.0 - $410.68 $15,092 - $18,069
44 Added 0.81%
5,467 $2.22 Million
Q3 2023

Oct 05, 2023

BUY
$338.18 - $362.46 $103,144 - $110,550
305 Added 5.96%
5,423 $1.89 Million
Q2 2023

Jul 10, 2023

SELL
$314.42 - $351.91 $63,512 - $71,085
-202 Reduced 3.8%
5,118 $1.8 Million
Q1 2023

Apr 19, 2023

BUY
$283.23 - $323.1 $118,673 - $135,378
419 Added 8.55%
5,320 $1.68 Million
Q4 2022

Jan 13, 2023

BUY
$285.76 - $321.48 $126,591 - $142,415
443 Added 9.94%
4,901 $0
Q3 2022

Oct 19, 2022

BUY
$273.83 - $305.53 $306,141 - $341,582
1,118 Added 33.47%
4,458 $1.31 Million
Q2 2022

Jul 20, 2022

BUY
$234.96 - $292.55 $380,635 - $473,931
1,620 Added 94.19%
3,340 $941,000
Q1 2022

Apr 11, 2022

BUY
$221.42 - $260.97 $380,842 - $448,868
1,720 New
1,720 $449,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $133B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Harbour Capital Advisors, LLC Portfolio

Follow Harbour Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbour Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Harbour Capital Advisors, LLC with notifications on news.